Bianca Muñiz, a three-time cancer survivor first diagnosed at age 11, shared her powerful story on International Childhood ...

Ovarian cancer vaccines are under development, but none are ready for primetime. There are no screening tools for ovarian ...

The 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in advanced ovarian cancer and other solid tumours. Suitable for ...

AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...

University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...

Her latest chapter? Returning to school to earn a master’s degree at the University of Tennessee, Knoxville. In 2016, after an ovarian cancer diagnosis, Sharon was given less than four years to live.

It induces a specific type of immunity, called Th17 immunity, that seems to prevent suppression of the immune system. The ...

Ovarian cancer is the sixth most common cancer in women in the UK but the symptoms can be quite subtle, often leaving to a ...

Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...